Table 1.
Participant sociodemographic, disease, and reproductive characteristics by diagnosis
| Participant characteristics | Total cohort (N=129) | Ulcerative colitis (n=52) | Crohn’s disease (n=77) | p |
|---|---|---|---|---|
| Sociodemographic characteristics | ||||
| Mean age (SD)* (years) | 34.3 (6.2) | 34.4 (6.2) | 34.2 (6.3) | 0.9 |
| Race (%)† | 0.7 | |||
| Caucasian | 110 (85.3) | 46 (88.5) | 64 (83.1) | |
| African American | 17 (13.2) | 6 (11.5) | 11 (14.3) | |
| Declined | 2 (1.6) | 0 (0) | 2 (2.6) | |
| Hispanic ethnicity‡ | 8 (6.2) | 4 (7.7) | 4 (5.2) | 0.6 |
| Education† | 0.9 | |||
| High school | 4 (3.1) | 1 (1.9) | 3 (3.9) | |
| Some college/bachelor | 71 (55.0) | 26 (50.0) | 45 (58.4) | |
| Graduate/professional | 54 (41.9) | 25 (48.1) | 29 (37.7) | |
| Married/committed relationship‡ | 71 (55.1) | 33 (63.5) | 38 (49.4) | 0.1 |
| Disease characteristics | ||||
| Median number of months since diagnosis (range)§ | 116 (9–338) | 144 (9–298) | 112 (18–338) | 0.7 |
| Prior IBD-related surgery‡ | 38 (29.5) | 7 (13.5) | 31 (40.3) | <0.01 |
| Median number of IBD-related hospital admissions (range)§ | 1 (0–100) | 1 (0–25) | 1 (0–100) | 0.01 |
| Current medications‡ | ||||
| Aminosalicylates | 60 (46.5) | 36 (69.2) | 24 (31.2) | <0.01 |
| Immunomodulators | 40 (31.0) | 11 (21.2) | 29 (37.7) | 0.05 |
| Systemic steroids | 9 (7.0) | 4 (7.7) | 5 (6.5) | 0.8 |
| Biological therapies | 45 (34.9) | 7 (13.5) | 38 (49.4) | <0.01 |
| Reproductive history | ||||
| Mean age menarche (SD)* (years) | 12.9 (1.7) | 12.9 (1.8) | 12.9 (1.6) | 0.89 |
| Nulliparae‡ | 65 (50.4) | 26 (50.0) | 39 (50.6) | 0.94 |
| Median parity (range)§ | 0 (0–4) | 0 (0–4) | 0 (0–4) | 0.94 |
| Contraceptive method¶ | 0.19 | |||
| No method | 41 (31.8) | 18 (34.6) | 23 (29.9) | |
| Condoms | 13 (10.1) | 6 (11.5) | 7 (9.1) | |
| Combination pills, patch or ring | 41 (31.8) | 11 (21.2) | 30 (39.0) | |
| LNG-IUS, Cu-IUD, or implant | 34 (26.4) | 17 (32.7) | 17 (22.1) | |
| Desiring future pregnancy‡ | 73 (56.6) | 27 (51.9) | 46 (59.7) | 0.38 |
| IBD-related pregnancy concerns‡ | 68 (52.7) | 20 (38.5) | 48 (62.3) | 0.01 |
Entries in the table represent the number of participants (percentage) unless otherwise specified.
IBD medication classes: Aminosalicylates include balsalazide, sulfasalazine, mesalamine and olsalazine. Immunomodulators include azathioprine, 6-mercaptopurine and methotrexate. Topical or systemic steroids include hydrocortisone enemas, suppositories and other formulations, budesonide, prednisone, methylprednisolone and prednisolone. Biological therapies include infliximab, adalimumab, certolizumab and natalizumab.
t-test.
Fisher’s exact test.
Two-sample test of proportions.
Wilcoxon rank sum test.
Chi-square (χ2) test.
Cu-IUD, copper intrauterine device; IBD, inflammatory bowel diseases; LNG-IUS, levonorgestrel intrauterine system; SD, standard deviation.